FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a method for reverse development or prevention of cognitive impairment in a patient to whom an NMDA receptor antagonist is introduced, comprising administering an effective amount of GLYX-13, wherein the NMDA receptor antagonist is ketamine or phencyclidine. Invention also relates to a method of treating a neurological disorder or stroke, psychosis, pain, depression, Parkinson's disease, Alzheimer's disease, a method of treating a central nervous system disease, a method of treating schizophrenia, a method of treating depression, a pharmaceutically acceptable composition.
EFFECT: use of the present invention enables neutralizing a side effect of the NMDA receptor antagonist.
25 cl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATION OF ATYPICAL ANTIPSYCHOTIC AND NMDA MODULATOR FOR TREATMENT OF SCHIZOPHRENIA, BIPOLAR DISORDER, COGNITIVE DISORDER, AND CLINICAL DEPRESSION | 2016 |
|
RU2802972C2 |
| CYCLOPROPYLPIPERIDINE GLYCINE TRANSPORTER INHIBITORS | 2005 |
|
RU2387644C2 |
| METHODS OF TREATING OR RELIEVING MIGRAINE | 2015 |
|
RU2721401C2 |
| STABLE COMPOSITIONS OF NEUROACTIVE PEPTIDES | 2015 |
|
RU2716164C2 |
| MEDICINAL AGENTS USED FOR PROPHYLAXIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | 2001 |
|
RU2258506C2 |
| MODULATOR OF NMDA-RECEPTOR WITH STABILISED SECONDARY STRUCTURE AND ITS USAGE | 2011 |
|
RU2566821C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508096C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING ATYPICAL NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508106C2 |
| PEPTIDE ANTAGONIST OF THE NMDA RECEPTOR | 2019 |
|
RU2716258C1 |
| THERAPEUTIC APPLICATION OF SELECTIVE INHIBITORS PDE10 | 2003 |
|
RU2303259C2 |
